scholarly journals Decrease of Consciousness Level Caused by Baclofen; a Case Report

Author(s):  
Hamideh Ebrahimi ◽  
Meimanat Hosseini

Abstract Background: The side effects of drug use can have different consequences, from allergies to death. Among the drugs used to relieve chronic spasms is baclofen. Baclofen is a gamma-aminobutyric acid (GABA) agonist that is commonly administered orally and acts on the spinal cord. A few studies have been reported on mortality from baclofen. Case presentation: This present study reported a case of decreased consciousness and drowsiness, and severe decrease in muscle tone as a result of taking only 50 mg of baclofen.Conclusion: Level of consciousness can be decreased following the administration of baclofen but it is not permanent. Nurses are recommended to check albumin level of the blood as an intervening factor and pay attention to patients’ responses to baclofen.

Medicina ◽  
2020 ◽  
Vol 56 (8) ◽  
pp. 387
Author(s):  
Francesco Calì ◽  
Maurizio Elia ◽  
Mirella Vinci ◽  
Luigi Vetri ◽  
Edvige Correnti ◽  
...  

The DHRS9 gene is involved in several pathways including the synthesis of allopregnanolone from progesterone. Allopregnanolone is a positive modulator of gamma aminobutyric acid (GABA) action and plays a role in the control of neuronal excitability and seizures. Whole-exome sequencing performed on a girl with an early onset epilepsy revealed that she was a compound heterozygote for two novel missense mutations of the DHRS9 gene likely to disrupt protein function. No previous studies have reported the implication of this gene in epilepsy. We discuss a new potential pathogenic mechanism underlying epilepsy in a child, due to a defective progesterone pathway.


1996 ◽  
Vol 84 (5) ◽  
pp. 1205-1214 ◽  
Author(s):  
Peggy Mason ◽  
Casey A. Owens ◽  
Donna L. Hammond

Background The hind brain and the spinal cord, regions that contain high concentrations of gamma-aminobutyric acid (GABA) and GABA receptors, have been implicated as sites of action of inhalational anesthetics. Previous studies have established that general anesthetics potentiate the effects of gamma-aminobutyric acid at the GABAA receptor. It was therefore hypothesized that the suppression of nocifensive movements during anesthesia is due to an enhancement of GABAA receptor-mediated transmission within the spinal cord. Methods Rats in which an intrathecal catheter had been implanted 1 week earlier were anesthetized with halothane. Core temperature was maintained at a steady level. After MAC determination, the concentration of halothane was adjusted to that at which the rats last moved in response to tail clamping. Saline, a GABAA, a GABAB, or glycine receptor antagonist was then injected intrathecally. The latency to move in response to application of the tail clamp was redetermined 5 min later, after which the halothane concentration was increased by 0.2%. Response latencies to application of the noxious stimulus were measured at 7-min intervals during the subsequent 35 min. To determine whether these antagonists altered baseline response latencies by themselves, another experiment was conducted in which the concentration of halothane was not increased after intrathecal administration of GABAA receptor antagonists. Results Intrathecal administration of the GABAA receptor antagonists bicuculline (0.3 micrograms) or picrotoxin (0.3, 1.0 micrograms) antagonized the suppression of nocifensive movement produced by the small increase in halothane concentration. In contrast, the antinocifensive effect of the increase in halothane concentration was not attenuated by the GABAB receptor antagonist CGP 35348 or the glycine receptor antagonist strychnine. By themselves, the GABAA receptor antagonists did not alter response latency in rats anesthetized with sub-MAC concentrations of halothane. Conclusions Intrathecal administration of bicuculline or picrotoxin, at doses that do not change the latency to pinch-evoked movement when administered alone, antagonized the suppression of noxious-evoked movement produced by halothane concentrations equal to or greater than MAC. These results suggest that enhancement of GABAA receptor-mediated transmission within the spinal cord contributes to halothane's ability to suppress nocifensive movements.


2021 ◽  
Author(s):  
Xiaojie Liu ◽  
Jihui Yin ◽  
Zhen Hua ◽  
Haichen Chu

Abstract BackgroundPrevious study has illustrated that the factors can affect the duration of neuromuscular blockade. Vegetarian habits may affect osteoporosis and respiratory muscle tone.Case PresentationThe purpose of this report is to record the first unusual prolonged neuromuscular block by concomitant clindamycin in a vegetarian. ConclusionClinical doses of clindamycin may significantly prolong the neuromuscular blockade of “short-acting” no depolarizing muscle relaxants when the patient is so weak and vegetarian. This requires vigilance and routine monitoring of the neuromuscular junction by the anesthesiologist.


1985 ◽  
Vol 63 (10) ◽  
pp. 1297-1301 ◽  
Author(s):  
C. L. Girard ◽  
J. R. Seoane ◽  
J. J. Matte

Fourteen sheep were used to study the role of gamma-aminobutyric acid (GABA) on the hypothalamic control of feed intake. Injections (1 μL) of pentobarbital (262 nmol) into preoptic and paraventricular areas induced feeding in satiated sheep. Injections of GABA into the same loci gave variable results, probably because the neuronal and glial uptake of GABA limits its effects. Muscimol, a GABA agonist with a higher affinity for postsynaptic GABA receptors than GABA, injected at doses from 0 to 0.750 nmol, gave a cubic dose–response curve; the highest feed intake was measured at 0.5 nmol. The response induced by muscimol was blocked by preinjections of two GABA antagonists, picrotoxin and bicuculline, with picrotoxin being more effective than bicuculline. Muscimol responsive loci were identified mainly in the preoptic, paraventricular, and anterior hypothalamus. The data suggests that neurons sensitive to gamma-aminobutyric acid may be implicated in the control of feed intake in sheep.


Neurosurgery ◽  
1994 ◽  
Vol 34 (3) ◽  
pp. 484-489 ◽  
Author(s):  
Bengt Linderoth ◽  
Carl-Olav Stiller ◽  
Lal Gunasekera ◽  
William T. O'Connor ◽  
Urban Ungerstedt ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Tania Ahuja ◽  
Ofole Mgbako ◽  
Caroline Katzman ◽  
Allison Grossman

This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome.


Sign in / Sign up

Export Citation Format

Share Document